Application and survival analysis of furmonertinib in treating brain metastasis of non-small cell lung cancer
10.3969/j.issn.1009-0754.2024.12.020
- VernacularTitle:伏美替尼在非小细胞肺癌脑转移中的应用效果及生存分析
- Author:
Huan CHEN
1
;
Yigen LIU
;
Sun WU
;
Lixia DUAN
Author Information
1. 246000 安徽安庆,安庆一一六医院呼吸与危重症医学科
- Keywords:
Non-small cell lung cancer;
Brain metastasis;
Furmonertinib;
Survival analysis
- From:
Journal of Navy Medicine
2024;45(12):1317-1321
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of furmonertinib in the treatment of brain metastasis from non-small cell lung cancer(NSCLC)and its impact on survival and prognosis.Methods The medical records of 76 patients with NSCLC brain metastasis who were admitted to Anqing Hospital of Navy from March to December 2021 were retrospectively analyzed.According to the treatment plan,they were divided into study group(33 cases)and control group(43 cases).The control group was treated with whole brain radiotherapy,and the study group was given oral furmonertinib on the basis of the control group.After 3 months of treatment,disease control rate,objective remission rate,serum tumor marker levels and adverse drug reactions were compared between the two groups.All the patients were followed up for 12 months,and the overall survival(OS)and progression free survival(PFS)were recorded.Results The objective remission rate and disease control rate in the study group were higher than those in the control group(P<0.05).After 3 months of treatment,serum carcinoma embryonic antigen(CEA)and cytokeratin 19 fragment(CYFRA21-1)were decreased in both groups,and the two indexes in the study group were lower than those in the control group(P<0.05).The PFS of the study group and control group were 7.5 months and 5.0 months,respectively.The one-year OS of the study group and control group was 75.00%and 52.50%,respectively.There were statistically significant differences in the survival curves of PFS and one-year OS between the two groups(P<0.05).No significant difference was found in the incidences of myelosuppression,diarrhea,rash,cough,upper respiratory tract or oral mucosal infection between the two groups(P>0.05).The proportion of patients with increased transaminase in the study group was higher than that in the control group(P<0.05).Conclusion Furmonertinib can not only improve the objective remission rate and disease control rate of patients with NSCLC brain metastasis,but also effectively prolong the PFS and OS,with good safety.However,it may increase the risk of transaminase elevation.
